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Abstract: Bone metastases are a common complication of epithelial cancers, of which breast, prostate
and lung carcinomas are the most common. The establishment of cancer cells to distant sites such as
the bone microenvironment requires multiple steps. Tumour cells can acquire properties to allow
epithelial-to-mesenchymal transition, extravasation and migration. Within the bone metastatic niche,
disseminated tumour cells may enter a dormancy stage or proliferate to adapt and survive, interacting
with bone cells such as hematopoietic stem cells, osteoblasts and osteoclasts. Cross-talk with the bone
may alter tumour cell properties and, conversely, tumour cells may also acquire characteristics of
the surrounding microenvironment, in a process known as osteomimicry. Alternatively, these cells
may also express osteomimetic genes that allow cell survival or favour seeding to the bone marrow.
The seeding of tumour cells in the bone disrupts bone-forming and bone-resorbing activities, which
can lead to macrometastasis in bone. At present, bone macrometastases are incurable with only
palliative treatment available. A better understanding of how these processes influence the early
onset of bone metastasis may give insight into potential therapies. This review will focus on the early
steps of bone colonisation, once disseminated tumour cells enter the bone marrow.
Keywords: bone; metastasis; cancer; microenvironment; metastatic niche
1. Introduction
Bone metastases are a frequent complication of solid cancers [1]. The establishment of bone
metastasis is a considerable cause of morbidity, often resulting in bone pain, spinal cord compression,
hypercalcemia and pathological fractures, ultimately resulting in the need for surgery [2]. Different
tumours have varying levels of propensity to metastasise to the bone. Solid epithelial cancers are
prone to develop bone metastasis, notably breast and prostate cancer, but also to a lesser extent lung,
kidney and melanoma. Bone metastases are observed to affect 65%–75% of advanced breast and
prostate cancer patients [3]. These cells have a particular affinity for bone: this may be due to the
expression of genes that predispose them to home to the bone marrow, although it is also possible that
these cells acquire osteomimicry after localisation within the bone compartment. Bone metastases are
predominantly osteoblastic in prostate cancer, and a mixture of osteolytic and osteoblastic in breast
cancer [2].
The establishment of cancer cells in the bone marrow requires multiple steps, whereby cells need
to leave the primary tumour and then adapt and survive in a physiologically different environment.
The local microenvironment, or premetastatic niche, may be modified through the secretion of factors
by cancer cells to establish favourable conditions for metastasis. For instance, cancer cell secretion
of lysyl oxydase (LOX) is able to increase extracellular rigidity by reticulation of collagen and thus
promote cancer cell anchorage [4]. In order to extravasate and survive in the circulation, tumour
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cells commonly undergo epithelial to mesenchymal transition (EMT), which allows cells to adopt a
mesenchymal-like phenotype. These steps are essential for tumour cells to seed to distant sites such as
bone [5,6]. This process plays a pivotal role in the initial steps of the metastatic cascade (reviewed in [7]).
EMT is defined by the loss of epithelial markers (claudin, cytokeratin, and E-cadherin) and the gain of
mesenchymal markers (N-cadherin, vimentin, fibronectin, and smooth muscle actin). Tumour cells
that have begun the process of EMT lose expression of molecules responsible for cell-cell junctions such
as E-Cadherin and β-catenin by the action of well-described EMT-actors such as Snai1, Twist, Slug and
Zeb1/2 transcription factors. In parallel, tumour cells acquire the capacity to be motile by expressing
N-Cadherin and vimentin, which are responsible for cytoskeleton rearrangement and lamellipodia
formation. The ability for cells to undergo EMT is thought to be related to the ability to self-renew and
differentiate into different tumour cell types, also known as “stemness” and adaptability, leading to
resistance to chemotherapy [7,8]. It is generally acknowledged that disseminated tumour cells (DTCs)
are required to undergo EMT-reversal. This process is known as mesenchymal-to-epithelial transition
(MET) whereby cells regain their epithelial phenotype to seed to themetastatic niche, allowing adhesion
and anchorage independent growth [9,10]. Hepatocyte-growth factor (HGF) stimulated Twist1 activity,
which was shown to positively regulate the MET phenotype to promote breast cancer cell metastasis
to bone [10].
Tumour cells that settle in the bone marrow enter a dormant state in specific niches and/or adapt
to the bone microenvironment (osteomimicry). Disseminated tumour cells (DTCs) may become active
years later as they proliferate and alter the functions of bone-resorbing (osteoclasts) and bone-forming
(osteoblasts) cells, disrupting physiological bone remodelling and promoting skeletal destruction.
In turn, the release of bone-derived growth factors (transforming growth factor β (TGFβ) or insulin-like
growth factor 1 (IGF-1)) and calcium (Ca2+) from resorbed bone promote tumour growth [11,12].
This review will focus on the molecules involved in tumour cell dissemination, its homing
within the metastatic niches, the establishment of micrometastases and regulation of tumour cell
dormancy. Finally, secreted factors which influence bone destruction or tumour cell seeding in the
bone microenvironment will also be discussed.
2. Osteotropism
2.1. Cancer Cell Migration to the Bone
For cancer cells to migrate from the primary tumour to the bone, the migration of cancer cells
may be triggered by chemotaxis in response to different stimuli. The mechanisms by which the
breast carcinoma cells migrate and colonise the bone marrow are still only partially understood.
While Paget has developed the hypothesis of the “seed and soil” to explain tumour cell tropism to
a specific organ [13], it is now clearly recognised that there is a genetic determinant in tropism and
the bone colonisation process. Massagué et al. has demonstrated a “molecular signature” acquired by
cancerous cells within the primary tumour, allowing them to spread and colonise the bone marrow [14].
This molecular signature includes genes originally involved in bone physiology and these genes are
mirrored in the tropism of tumour cells to the bone. Indeed, tumour cells use the same mechanisms
employed by hematopoietic stem cells (HSC) and leucocytes to migrate to the bone. This process
involves receptors expressed by tumour cells and ligands expressed by the bone microenvironment
(Figure 1A).
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Figure 1. Stages of cancer cell colonisation of the bone. (A) Tumour cells are attracted to the high
levels of chemoattractants in the bone marrow (red), such as Ca2+, CXCL12 (C–X–C motif chemokine
ligand 12) and RANKL. In the endosteal niche, hematopoietic stem cells (HSC) and disseminated
tumour cells (DTCs) competitively bind to osteoblasts through interactions between CXCR4/CXCL12
and Annexin II/Annexin II receptor. In addition, expression of E-cadherin on the DTC surface can
form adherin junctions with N-cadherin expressing osteoblasts as well as form interactions between
RANK and RANKL, the latter of which is secreted by osteoblasts and osteocytes. Furthermore, DTCs
also express integrins which can interact with a number of factors in the bone marrow (VCAM-1, bone
sialoprotein (BSP), osteopontin (OPN), victronectin); (B) Once in the bone marrow, DTCs compete
with HSCs for the endosteal niche. DTCs are able to proliferate; although a majority of cells die or
remain dormant. The local environment has a significant impact on the fate of these DTCs. Local
levels of type I collagen and fibronectin have been demonstrated to repress dormancy. Dormant cells
have been reported to be found in the vascular niche, in close proximity to capillaries and within
regions rich in CXCL12 and E-selection. The vascular niche is able to secrete thrombospondin-1
(TSP1) and Notch-1, which are important for maintaining dormancy. Several studies also show
TGFβ2, can play an important role in the maintenance of dormancy through MAPK signalling, while
TGFβ1 secreted from neovascular tips is associated with tumour cell reactivation. Periostin can also
be secreted by neovascular tips as well as Cancer Stem Cells (CSCs), leading to DTC reactivation.
The endosteal (osteoblastic) niche can also maintain tumour cell dormancy through the secretion of
GAS6 by osteoblasts and OPN and angiopoietin-1 by spindle-shaped N-cadherin+ osteoblasts (SNOs).
To exit dormancy, osteoclasts are able to release stem cell signals, triggering the NFκB pathway. We also
know that the release of Ca2+ from normal bone remodelling can bind to calcium sensing receptor
(CaSR) to stimulate PTHrP, leading to tumour cell reactivation; (C) After DTCs are reactivated, they
become proliferative and establish macrometastases. Bone matrix derived TGFβ, IGF, PDGF and
BMP can promote tumour cell proliferation, as well as Cancer Associated Fibroblasts (CAFs) secreted
CXCL12. Once macrometastases are established, the tumour can release factors that drive osteoclasts
(M-CSF, TNFα, IL-11 and IL-8) to induce osteolytic lesions through the stimulation of RANKL. Tumour
cells have also been shown to release miRNAs that stimulate osteogenesis through the down-regulation
of DKK-1 and SOST-1. Finally, association of tumour cells with the endosteal niche has been associated
with tumour cell growth.
The main molecules involved in HSC and tumour cell migration are couple chemokine (C–X–C)
receptor type 4 (CXCR4) and 6 (CXCR6) and their respective ligands, C–X–C motif chemokine
ligand 12 (CXCL12) and 16 (CXCL16). In healthy breast and prostate epithelial cells, CXCR4 and
CXCR6 are not expressed, but their expression levels are significantly increased in invasive cancer
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cells [15,16]. In the bone marrow, osteoblasts constitutively express CXCL12, which can act in
unison with sphingosine-1-phosphate (S1P) as a chemo-attractant to regulate HSC homing [15,17].
For HSC, activation of CXCR4 by CXCL12 triggers migration to the bone marrow. In the same manner,
overexpression of CXCR4 in breast cancer cell lines increased bone metastasis formation in animal
models [14]. Inhibition or over-expression of CXCR4 modifies cancer cell propensity to colonise bone
marrow [18,19]. Similarly, inhibition of CXCR4 by pharmacological agents or neutralising antibodies
decreases metastatic cancer cell dissemination to the lung and bone [19,20]. CXCL16 is expressed
in vivo by bone tissue, including osteocytes [21]. It acts as an in vitro chemotactic agent to promote
the migration of CXCR6-expressing prostate cancer cells (PC3 cell line) and therefore promote the
formation of bone metastases [21].
High extracellular Ca2+ concentration as a result of normal bone remodelling has been
demonstrated to act as a chemoattractant for breast cancer cells in vitro [22]. This was shown to be
due to Ca2+ acting on calcium sensing receptor (CaSR), in line with the role of CaSR in the localisation
of HSCs to the bone marrow due to high local Ca2+ levels (Figure 1A) [23]. This relates to the
“vicious cycle”, which was described by Mundy et al., whereby tumour cells interact with the bone
microenvironment to drive disease progression [24]. Under this system, osteoclast-mediated bone
resorption occurs when Ca2+ binds to CaSR which can in turn stimulate PTHrP in cancer cells in a
feed-forward loop [11]. A recent study in breast cancer showed that CaSR stimulates intracrine PTHrP
signalling, promoting tumour cell proliferation and survival [12].
In addition, the receptor activator of NFκB ligand (RANKL) is produced by osteoblast in bone
and the RANK/RANKL pathway has a key role in osteoclast differentiation [25]. RANK is expressed
in several breast and prostate cancer cell lines as well as primary human breast tumours and has
been demonstrated to be an important driver of cancer cell migration to the bone [26,27]. RANKL is
also a mediator of osteoclast function and survival and is negatively regulated by a decoy receptor,
osteoprotegerin (OPG) [25,28]. Direct contact between breast cancer cells and osteoblastic cells induced
RANKL and OPG expression by cancer cells [29]. Jones et al. showed RANK-expressing breast
and prostate cancer cell lines treated with recombinant RANKL stimulated migration, which was
blocked by the decoy receptor OPG [27]. Importantly, osteocytes are a major source of RANKL in
adulthood [30–32], and there is some evidence in the literature that osteocytes contribute to bone
metastasis formation by favouring cancer cell colonisation in the bone marrow [31,32]. Osteoblasts
also express Annexin II, which has been shown to promote tumour cell tropism to bone. This has
been demonstrated in Annexin II receptor-expressing prostate cancer cells which migrate toward
Annexin II [33].
2.2. Cell Adhesion
An important part in the mestastatic cascade, loss of cell-adhesion is firstly demonstrated to allow
cells to dissociate from the surrounding matrix in order to extravasate into the circulation [34]. After the
cell enters the bone marrow, the ability for cells to regain adhesiveness is essential for cell-anchorage.
Tumour cells arrive in a complex environment and because they express the same surface molecules as
HSCs, tumour cells can be anchored in the bone marrow (Figure 1A). In the bone marrow, HSCs are
housed in anatomical entities called “niches”. Each of these niches regulates anchorage, quiescence
and proliferation, which will be described in the following section. Several molecules are also known
to participate in enhanced adhesion in bone, summarised in Table 1. This includes adherin-junctions
within the osteogenic niche, formed by the association of mesenchymal N-cadherin and breast cancer
cells which express E-cadherin [35]. Integrins are also important mediators of anchorage of HSCs,
since they bind to several extracellular matrix factors and have been shown to be involved in adhesion,
migration and invasion to the bone. Integrins αvβ3 and αvβ5 are capable of binding to important bone
matrix proteins, bone sialoprotein (BSP), osteopontin (OPN) and vitronectin [36,37]. Integrin αvβ3
is expressed by breast and prostate cancer cells, and overexpressed in an osteotropic model of breast
cancer derived from MDA-MB-231 cells, called B02 [38]. Overexpression of integrin αvβ3 increased
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bone metastasis formation; treatment with non-peptide antagonists blocked bone colonisation in
integrin αvβ3-overexpressing cancer cells [38]. Moreover, 66C14 murine cancer cells which specifically
metastasise to the lung exhibited bone tropism after overexpression of integrin αvβ3 [39]. Integrin
α4β1 (VLA-4) is also expressed by tumour cells and allows their adhesion through its interaction
with vascular cell adhesion molecule-1 (VCAM-1) expressed by stromal cells in the bone marrow [40].
Further, osteoblasts and prostate cancer cells express annexin-II and its receptors, respectively, and
the adhesion of prostate cancer to osteoblasts, as well as the homing of prostate cancer cells to bone
in vivo, are limited by annexin II antibody [33].
Table 1. Key proteins for tumour cell regulation in the bone.
Function Protein Description Disease Reference
Homing
SIP SIP can act in unison with CXCL12 as a chemoattractant – [17]
CXCR4/CXCL12
CXCR4-expressing cancer cell migration to the bone is
mediated by osteoblast derived CXCL12.
Breast cancer
Prostate cancer
[19]
CXCR6/CXCL16
CXCL16 is expressed in bone tissue and promotes
migration of CXCR6-expressing cancer cells in vitro.
Prostate cancer [21]
Ca2+/CaSR
Ca2+ from bone remodelling stimulates
migration of CaSR-expressing cancer cells.
Breast cancer [23]
RANK/RANKL
RANK/RANKL axis promotes cancer cell migration
by mediating cytoskeleton rearrangement in vitro.
Breast cancer
Prostate cancer
[27]
Annexin II/Annexin IIR
Annexin II produced by osteoblast and
endothelial cells promotes the migration of
cells expressing annexin II receptor.
Prostate cancer [33]
Adhesion
CXCR4/CXCL12
CXCL12 in media from human primary bone-marrow
has chemotactic properties. Blocking with neutralising
CXCR4 antibodies impaired migration.
Breast cancer [15]
Annexin II/Annexin IIR
Annexin II is produced by endothelial and
osteoblast cells and promotes adhesion of
tumour cells expressing annexin II receptor.
Prostate cancer [33]
E-cadherin/N-cadherin
E-cadherin was found to be expressed by cancer cells
and form adherin junctions with N-cadherin in
osteogenic cells.
Breast cancer [35]
Integrin αVβ3 and αVβ5
Tumour cells expressing integrin αVβ3 and/or αVβ5
have the capacity to bind bone extracellular proteins
such as fibronectin, vitronectin and osteopontin.
Breast cancer [37,38]
Integrin α4β1/VCAM1
Integrin α4β1 expression by myeloma cells allow bone
cells to bind through VCAM1 interactions.
Multiple myeloma [40]
Survival
Periostin
CSCs were shown to modify the metastatic niche
through stromal periostin expression.
Breast cancer [41]
Src
Src-associated gene signature is linked with late-onset
bone metastasis. Src activity has been reported in cancer
cells “primed” for metastasis in the bone marrow.
Breast cancer [42,43]
Dormancy
E-selectin and CXCL12
Vascular regions are rich in E-selectin and CXCL12,
which is associated with HSC dormancy.
– [44]
Gas6/Axl/Sky/Mer
GAS6 is secreted by osteoblasts and is involved in
maintaining HSC quiescence.
Prostate cancer [45]
Angiopoietin-1 Involved in forming a quiescent niche for HSCs. – [46,47]
TSP-1
The secretion of TSP-1 from endothelial cells induces
cancer cell dormancy.
Breast cancer [48]
TGFβ 2/BMP7/SPARC
Indolent prostate cancer cells secrete SPARC, which can
promote BMP7-mediated senescence.
Prostate Cancer [49,50]
BMP7
BMP7 is secreted from bone stromal cells and induces
senescence in prostate cancer stem-like cells.
Prostate cancer [49]
Reactivation
TGFβ1 Secreted TGFβ1 enhances tumour cell formation. – [51]
Integrin α4β1/VCAM1
VCAM1-expressing cancer cells recruit integrin α4β1+
osteoclast progenitors and initiate reactivation through
the vicious cycle.
Breast cancer [52]
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3. Disseminated Tumour Cells (DTCs) in the Bone Marrow
In a large-scale study of early-stage breast cancer patients, DTCs were identified in 30% of bone
marrow aspirates at time of diagnosis [53]. Similarly, DTCs were identified in the bone marrow for
90% of advanced-stage prostate cancer patients [54–56]. The processes that determine the fate of
DTCs in the bone marrow remain unclear; however, the presence of DTCs is reported to be a negative
prognostic indicator in breast and prostate cancer [53,57–60]. The influence of bone marrow niches on
DTCs and the molecules that maintain dormancy will be discussed in the following sections.
Bone Marrow Niches
Endosteal and vascular niches are crucial regulators of normal and malignant stem-cell behaviour
in the bone marrow. Quiescent HSCs are enriched in the endosteal niche lining the bone surface,
whereas the vascular niche is oxygenated and stimulates proliferation and differentiation of HSCs [61].
The adhesion molecule E-selectin which is selectively expressed by endothelial cells in the vascular
niche promotes HSC proliferation [44]. Further, expansion of the vascular niche for HSCs has
been demonstrated to be stimulated by Notch signalling in endothelial cells [62]. The proximity
of HSCs to the endosteal niche is responsible for osteoblast-driven maintenance and quiescence of
HSCs [61]. Specifically, this quiescence of HSCs seems to be dependent on the CXCL12/CXCR4 axis,
as treatment with small molecule CXCR4 antagonist AMD3100 rapidly mobilised HSCs from the bone
marrow [63]. Additional mechanisms are likely to be involved in maintaining HSC quiescence. For
instance, growth arrest-specific 6 (GAS6), a receptor for annexin-II, is expressed by osteoblasts and
mediates HSC quiescence [45]. Additionally, the endosteal niche is home to a particular spindle-shaped
N-cadherin+ osteoblast (SNO) cell population. SNOs regulate quiescence of HSC through interaction
with N-cadherin and secretion of angiopoietin and OPN [47].
Breast tumour cells were found to preferentially locate to osteoblast-rich regions following
chemical alteration of the endosteal niche with the bisphosphonate zoledronic acid [64]. Similarly,
ablation of the endosteal niche by conditional knock-out was shown to be critical for prostate tumour
cell growth in bone [65]. It has been shown that epithelial-like cancer cells interact with osteogenic
cells and other stromal cells in the bone microenvironment through interactions between E-cadherin
and N-cadherin [35]. Furthermore, biphoton analysis of fluorescently labelled cancer cells in the bone
marrow suggests the involvement of osteoblast lineage cells and that these cancer cells occupy the
same endosteal niche as HSCs [66]. Indeed, DTCs in the bone marrow interact with the endosteal and
vascular niches, influencing DTC proliferation and outgrowth. Recently, real-time in vivo microscopy
of breast tumour xenografts showed that dormant DTCs were preferentially located in E-selectin-rich
vascular regions [67]. The use of highly specific inhibitors of E-selectin inhibited entry of breast cancer
cells into the vascular niche, whereas inhibition of the CXCR-4/CXCL-12 axis induced mobilisation
of dormant breast cancer cells from the vascular niche into circulation [67]. These results [67] are in
contrast with previous findings showing that dormant prostate cancer cells, which express CXCR4,
compete with HSCs for endosteal niche support [65,68]. DTCs likely benefit from some additional
cues in the endosteal niche. A recent study reported that DTCs from prostate cancer cell lines in
the endosteal niche take on characteristics of cancer stem cells (CD133+/CD44+, increased KLF 4,
Bmi-1, and Nanog mRNA levels) (Figure 1B), a process which was controlled by GAS6-mediated
mTOR signalling [61]. Overall, this concept of niche support for DTCs is still in the early stages of
investigation, and warrants further investigation.
4. The Fate of DTCs in the Bone Marrow
4.1. Tumour Dormancy
Several clinical observations showed that DTCs in the bonemarrow do not proliferate immediately
but enter a state of dormancy, whereby a group of cancerous cells cannot grow beyond a certain
size [69]. It is possible that dormant DTCs never develop cancer or they can exit dormancy to form
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bone metastasis, potentially many years after diagnosis [70]. Several theories exist to explain how
DTCs remain dormant, with the bone microenvironment playing a crucial role in this phenomenon.
Tumour dormancy can be defined as when the cell arrests and enters a quiescent state (G0) [71].
Dormancy allows DTCs to adapt to the microenvironment while at the same time they are protected
from the immune system and different therapies. The bone microenvironment is composed of different
cell types important for the survival and maintenance of HSCs and potentially tumour cells [72]
(immune surveillance and survival will be discussed in the next section). Growth-arrested DTCs have
been found in close proximity to the perivascular niche [48]. Furthermore, dormant or slow-growing
prostate cancer cells have been demonstrated to localise to the endosteal niche [68].
As discussed, the annexin II and its receptor are expressed by osteoblasts and prostate cancer
cells, respectively [33]. The binding of prostate cancer cells to annexin II induces the expression of
the growth arrest-specific GAS6 receptors Axl, Sky and Mer, which in the hematopoietic system,
induces dormancy [45]. In addition, GAS6 produced by osteoblasts prevents prostate cancer cell
proliferation and protects prostate cancer cells from chemotherapy-induced apoptosis [45]. Axl,
and hypoxia-inducible factor-1α (HIF-1α) were co-expressed in prostate cancer tissue and bone
metastases [73]. In hypoxic environments such as tumours and the bone microenvironment, it is
suggested that tumour mass is restricted by the lack of sufficient vascularisation [71]. One study
showed that stable bone microvasculature maintained a dormant niche by promoting tumour cell
quiescence through Notch-1-mediated regulation of neovascular tips and the angiocrine tumour
suppressor functions of thrombospondin-1 (TSP-1) [48].
TGFβ2 is a bone marrow derived factor which promotes DTC dormancy through TGFβ-R3 and
MAPK p38α/β signalling [51]. In the same study [51], treatment with TGFβ1 switched off dormancy,
leading to rapid tumour growth in vivo, suggesting that TGFβ2 alone is a mediator of dormancy. It is
possible that TGFβ regulation of dormancy could act through the bone morphogenetic protein (BMP)
pathway. This signalling pathway is well characterised in bone formation [74]. Recently, indolent
prostate cancer cells have been reported to secrete SPARC, which can induce BMP7 secretion by bone
marrow stromal cells [50], further supporting the role of BMP7 in inducing prostate cancer stem cell
senescence [49].
4.2. Survival
It is generally accepted that a majority of DTCs do not survive, due to the inefficient metastatic
process. The bone marrow has been postulated to provide survival signals, whereby the bone marrow
may be a protective environment for DTCs in patients undergoing chemotherapy [75,76]. For cancer
cells to be established in the bone, they will need to adapt to the new microenvironment to survive
and proliferate [77–79]. In one study, breast cancer stem cells were demonstrated to modify the
metastatic niche through the secretion of stromal periostin [71]. Fibroblast cells adjacent to tumour
cells, also known as cancer-associated fibroblasts (CAFs), can be altered by neighbouring tumour
cells. In one study, treatment with conditioned medium from the breast cancer cell line SUM102
elevated levels of CXCR4 in CAFs [80]. Furthermore, CAFs have also been reported to secrete high
levels of CXCL12 which were demonstrated to enhance the proliferation of breast cancer cells [81].
Intriguingly, CAFs secreted higher levels of CXCL12 than the breast cancer cell line MCF-7, which
promoted tumour growth and angiogenesis through the recruitment of endothelial progenitor cells.
This suggests that CAFs are able to act independently of tumour cells to further exacerbate the bone
metastasis cascade. In this way, it is proposed that CAFs can add selection pressure to heterogeneous
tumour cell populations, priming them for bone metastasis through exposure to CXCL12 and IGF1 [43].
“Primed” cancer cells were found to exhibit enhanced Src activity and bone metastatic ability. This is
supported by a previous study, whereby intracellular Src enhanced PI3K-AKT signalling through
stromal CXCL12, resulting in increased breast cancer metastasis to the bone marrow [42]. Fibroblasts
from the bone marrow stroma have also been reported to secrete factors that may play a part in cancer
cell metastasis in the bone [82].
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Bone turnover may have an important role on bone metastasis [83,84]. In ovariectomised mice,
no effect was observed for initial tumour cell numbers in the bone compared to sham operated mice,
suggesting that ovariectomy does not affect tumour cell homing, however breast cancer cell colonies
were increased [85]. Gene expression analysis showed increased RANKL and DKK-1 and decreased
OPG; this was accompanied by increased MMP-9 and cathepsin K activity, suggesting increased bone
resorption through elevated osteoclast activity [85]. This was proposed to be due to the stimulation of
the mesenchymal stem cell niche and thereby promote DTC proliferation [86]. Similar to the breast
cancer model, castration in mouse models of prostate cancer resulted in osteoclastic bone resorption,
which increased bone metastasis [87]. This work supports the clinical observation that higher bone
turnover is associated with poorer outcome in patients with bone metastasis [88–91].
In addition, the immune system is also involved in reducing tumour cell proliferation through
a process known as “immune-surveillance”, which balances proliferating cells and dying cells [92].
This is the process whereby immune cells detect and/or eliminate tumour cells. Tumour cells have been
reported to find refuge in the bone, promoting DTC survival [93]. This has been postulated to be due
to a dampened immunity which protects HSCs in the bone compartment [93]. The same mechanisms,
which maintained HSC quiescence, are also implicated in tumour cell dormancy (CXCR4, CXCL12
and angiopoietin-1) [46]. To adapt, survive and grow in the bone microenvironment, cancer cells must
mimic bone cells (osteomimicry) through the expression of molecules and factors usually expressed by
osteoblasts or osteoclasts. Paired immunochemistry on primary breast tumour samples and associated
liver, lung or bone metastases showed that only bone metastatic cancer cells express bone proteins
such as cathepsin K, osteonectin, cadherin-11, connexin-43 and RUNX2 [94,95]. Moreover, some
experiments have shown that cancer cells can fuse with macrophages or induce multinucleated giant
cells by fusion with osteoclast precursors, leading to cancer cells with osteoclast properties [96]. Breast
cancer cells express a number of osteoclast acting factors (PTHrP, IL-11, IL-6, TNFα, M-CSF) to promote
RANKL. The expression of these molecules may confer a survival advantage in immunosurveillance
or in the active colonisation of the bone marrow [75].
4.3. Reactivation
The latency period observed in metastatic relapse refers to the time for DTCs to adapt and
escape the metastatic niche (Figure 1B). Interestingly, the role of the vascular niche in maintaining
tumour cell dormancy is not so clear-cut, and that sprouting neovasculature can promote metastatic
outgrowth as a result of active TGFβ1 and periostin secreted from endothelial tip cells [48]. Within
the metastatic niche, extracellular Ca2+ can also activate dormant tumour cells [97]. However, recent
evidence in multiple myeloma showed that dormant tumour cell reactivation is dependent on its
localisation within the metastatic niche. That is, extrinsic factors from the endosteal niche are able
to “switch on” dormant tumour cells [97]. For instance, breast cancer cell expression of VCAM-1 has
been shown to bind with integrin α4β1 to promote the recruitment of osteoclast precursors, leading to
tumour cell reactivation [52]. Tumour cell development of an osteoclastic niche creates a shift in bone
homeostasis, triggering the release of stem cell signals to stimulate metastatic outgrowth, possibly
through the NFκB pathway [52]. Therefore, DTC reactivation also depends on intrinsic factors from
the tumour cells to permit self-renewal (cancer stem cell-like) in addition to environmental factors
from the metastatic niche.
In addition to the metastatic niche, a number of proteins have been reported to be able to reactivate
dormant DTCs. For instance, microenvironments rich in type I collagen [97,98] or fibronectin [99]
have been associated with diminished dormancy. Cathepsin K, which is secreted by osteoclasts, has
been shown to cleave MMP-9 [100] and CXCL12 [101]. Disruption of these proteins may perturb bone
homeostasis and result in the mobilisation of hematopoietic progenitors, thereby promoting DTC
activation [70,101]. In human breast cancer cells, the expression of inhibitor of differentiation 1 (ID1)
and 3 (ID3) has been demonstrated to reinitiate metastatic colonisation through bypassing senescence
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and promoting extravasation [102]. Further, DTC reactivation may be regulated by TGF-β, which can
induce ID1 [103].
5. Tumour Outgrowth and Secretion of Factors
Metastatic cancer cells are not solely responsible for the destruction of bone. This process mainly
involves osteoblasts and osteoclasts and they are essential for metastatic tumour cell establishment in
the bone (Figure 1C). Osteoblast production of RANKL/OPG can also regulate osteoclast formation
through PTHrP, interleukins (IL-1, and IL-6) and prostaglandin E2 (PGE2) [24]. Further, osteoclasts
were reported to stimulate RANKL on the osteoblast surface in mouse models of breast cancer bone
metastasis [104]. Activated TGFβ, IGFs, PDGF and BMP family members released from the bone
matrix have also been shown to enhance tumour cell proliferation [105,106].
In addition, osteoclasts can secrete factors that promote tumour growth such as microRNAs
(miRNAs), some of which have been shown to modulate bone function [107]. A number of miRNAs
have been reported to be differentially expressed following RANKL-induced osteoclastogenesis in
murine preosteoclast RAW264.7 cell lines [108,109]. Interestingly, the same study demonstrated that
treatment of conditioned media from bone-metastatic cells (4T1.2 and TSU-Pr-1-B2) were found to
induce osteoclast differentiation similar to that induced by RANKL [108]. This was further confirmed
by mammosphere assays whereby breast cancer cells co-cultured with osteoblast precursors were able
to accelerate tumour cell proliferation; this effect was not observed in monocyte co-cultures or after
differentiation to osteoclasts [35]. Moreover, exosome-like vesicles secreted from tumour cells were
able to significantly impair bone metastasis [110]. This further substantiates our understanding of how
secreted factors, including miRNAs, are able to regulate adjacent cells in a paracrine manner.
In addition to miRNAs, tumour cells can release factors that can interfere with normal bone
resorption. This includes inhibitors of osteoblast differentiation such as dickkopf-1 (DKK-1) and
sclerostin (SOST) [111]. Osteoclast activity has also been demonstrated to be stimulated by M-CSF,
TNFα and interleukins (IL-8, and IL-11) from breast cancer cells [111]. Finally, cathepsin K produced
by tumour cells has been shown to promote tumour cell invasiveness and contribute to bone
degradation [94,112].
6. Conclusions
While early detection and conventional treatments are effective for breast cancer management, the
development of bone metastasis remains a major cause of death. Patients diagnosed with bone cancer
are considered incurable. To date, no effective treatments for bone metastasis exist, only therapies
that aim to limit the bone degradation such as denosumab (anti-RANKL monoclonal antibody) and
bisphosphonates. In this review, we described the main mechanisms that allow cells to disseminate
and colonise in the bone marrow by highlighting the importance of the bone microenvironment. It is
clearly recognised that the tumour cells use the same processes as HSCs to migrate and anchor in the
bone marrow. Furthermore, the dormancy mechanisms give rise to the formation of bone metastases,
sometimes years after the detection of primary cancer. The study of DTCs in the bone marrow can be
improved through the implementation of different in vitro and in vivo models of the bone metastatic
niche [113]. Throughout this review, we have mentioned that osteocytes are the key producers of
RANKL, DKK-1 and SOST-1 in adult bone. As the most abundant bone cell, osteocytes may be
interesting drug targets, through the use of novel anti-resorptive and anabolic agents and monoclonal
antibodies against osteocyte-associated sclerostin (AMG 785 or romozumab) [114]. These agents are
currently under clinical trials for osteoporosis; however, a greater need for research in osteocytes in
the area of bone metastasis is desired. A better understanding of these mechanisms could lead to
new targets for treatments that could maintain cells in a non-proliferative state as well as prevent cell
anchorage in the bone marrow.
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